# Shilpa Medicare

Shilpa Medicare 全资子公司 Shilpa Biocare Private Limited 与总部位于芬兰的 Orion Corporation 就 Shilpa 的重组人白蛋白签署独家欧洲商业化协议（2026 财年第一季度 / 6 月下旬披露）——Orion 获得在欧洲的独家分销、营销与销售权；在等待 EMA 监管申报期间，将印度酵母发酵 rHSA 定位为欧洲血浆来源 HSA 的替代品；另有一家定性提及的英国企业 Albumedix（诺丁汉，Recombumin® 产品线，Sartorius 子公司），其作为全球关键厂商被 2026 年在线检索提及，但未浮现具体、可标注日期的 2026 年商业事件。

Source: https://cn.bioecon.ru/companies/shilpa-medicare/
Updated: 2026-08-15

- 国家: India
- 代码: BSE:530549

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 根据合作协议，公司从Orion Corporation获得研发和监管里程碑付款。 | https://pharmafile.com/news/shilpa-medicare-and-orion-partner-expanding-into-european-market/, https://vbshilpa.com/pdf/Investor%20Presentation%20-%2026%20May%202025.pdf, https://www.businesswire.com/news/home/20260703259800/en/Orion-and-Shilpa-Medicare-Expand-Partnership-to-Develop-and-Supply-Nivolumab-Biosimilar-for-Europe, https://www.orionpharma.com/newsroom/all-news/releases/press-releases/2025/orion-announces-agreement-with-shilpa-medicare-for-recombinant-human-albumin-for-european-market/, https://www.orionpharma.com/newsroom/all-news/releases/press-releases/2026/orion-pharma-announces-agreement-with-shilpa-medicare-for-nivolumab-biosimilar-for-european-market/, https://www.vbshilpa.com/pdf/Investor%20presentation%20for%20the%20quarter%20ended%2031%20March%202026.pdf, https://www.vbshilpa.com/pdf/strategic%20partnership%20with%20Orion%20Corporation,%20Finland.pdf |
| 产能 | 发酵产能逾200千升，其中产品罐容量5-50千升，缓冲罐容量5-15千升 | https://vbshilpa.com/pdf/Investor%20Presentation%20-%2026%20May%202025.pdf, https://www.bseindia.com/xml-data/corpfiling/AttachHis/d8fbdf4d-cadc-4d71-b78c-359c6dc287ea.pdf, https://www.vbshilpa.com/pdf/Investor%20presentation%20for%20the%20quarter%20ended%2031%20March%202026.pdf |
| 认证 | 生产设施持有多项认证，包括美国FDA、欧盟GMP、WHO-GMP、TGA、PMDA、KFDA、ANVISA、COFEPRIS及加拿大卫生部（Health Canada）。 | https://vbshilpa.com/, https://vbshilpa.com/pdf/Investor%20Presentation%20-%2026%20May%202025.pdf, https://www.bseindia.com/xml-data/corpfiling/AttachHis/d8fbdf4d-cadc-4d71-b78c-359c6dc287ea.pdf, https://www.vbshilpa.com/pdf/Annual-report-results-2024-2025.pdf, https://www.vbshilpa.com/pdf/Investor%20presentation%20for%20the%20quarter%20ended%2031%20March%202026.pdf |
| 监管批准 | 公司持续保持来自美国FDA、欧盟GMP、日本PMDA、韩国KFDA和澳大利亚TGA等机构的监管批准。 | https://vbshilpa.com/, https://vbshilpa.com/pdf/Investor%20Presentation%20-%2026%20May%202025.pdf, https://www.bseindia.com/xml-data/corpfiling/AttachHis/d8fbdf4d-cadc-4d71-b78c-359c6dc287ea.pdf, https://www.vbshilpa.com/pdf/Annual-report-results-2024-2025.pdf, https://www.vbshilpa.com/pdf/Investor%20presentation%20for%20the%20quarter%20ended%2031%20March%202026.pdf |
| 生产基地 | 设施包括Raichur的API 1号及2号厂区、Jadcherla及班加罗尔的制剂厂区,以及Dharwad的生物制品基地。 | https://vbshilpa.com/, https://vbshilpa.com/pdf/Investor%20Presentation%20-%2026%20May%202025.pdf, https://www.bseindia.com/xml-data/corpfiling/AttachHis/d8fbdf4d-cadc-4d71-b78c-359c6dc287ea.pdf, https://www.vbshilpa.com/pdf/Investor%20presentation%20for%20the%20quarter%20ended%2031%20March%202026.pdf |
| 员工人数 | 截至2026年3月全球共1,059名员工 | https://finance.yahoo.com/quote/SHILPAMED.NS/ |
| 营收 | 截至 2026 年 3 月 31 日的整个财年为 1,549 crore 印度卢比。 | https://www.bseindia.com/xml-data/corpfiling/AttachHis/d8fbdf4d-cadc-4d71-b78c-359c6dc287ea.pdf, https://www.bseindia.com/xml-data/corpfiling/AttachLive/33c87f15-3d6d-4a67-a887-1f40772259bf.pdf, https://www.vbshilpa.com/pdf/Investor%20presentation%20for%20the%20quarter%20ended%2031%20March%202026.pdf |

独立来源: bseindia.com, businesswire.com, finance.yahoo.com, orionpharma.com, pharmafile.com, vbshilpa.com

## 技术

- [重组人血清白蛋白（rHSA）](https://cn.bioecon.ru/technology/recombinant-human-serum-albumin/)